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Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disease of the skin and mucous membranes,
characterized by autoantibodies against type VII collagen (COL7), a major component of anchoring ﬁbrils.
Different clinical EBA phenotypes are described, including mechanobullous and inﬂammatory variants. Most EBA
patients’ sera react with epitopes located within the non-collagenous 1 (NC1) domain of human COL7. However,
it has remained unclear whether antibody binding to these different epitopes is pathogenically relevant. To
address this issue, we generated recombinant proteins covering the entire NC1 domain. IgG reactivity with these
proteins was analyzed in sera of 69 EBA patients. Most recognized clusters of epitopes throughout the NC1
domain. No correlation was detected between antibody speciﬁcity and clinical phenotype. To study the
pathogenicity of antibodies speciﬁc to different NC1 subdomains, rabbit antibodies were generated. All these
antibodies caused dermal–epidermal separation ex vivo. Antibodies against two of these subdomains were
injected into mice carrying null mutations of mouse COL7 and the human COL7 transgene and induced
subepidermal blisters. We here document that autoantibodies to COL7, independent of the targeted epitopes,
induce blisters both ex vivo and in vivo. In addition, using COL7-humanized mice, we provide in vivo evidence of
pathogenicity of autoantibodies binding to human COL7.
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INTRODUCTION
Autoimmune diseases are characterized by the presence of
autoreactive T or B cells that mediate an uncontrolled
inﬂammatory response and are responsible for clinical disease
manifestation (Rose and Bona, 1993). Over the past decades,
incidence of autoimmune diseases has constantly increased in
developed countries (Bach, 2002). Epidermolysis bullosa
acquisita (EBA) is a prototypical, organ-speciﬁc autoimmune
disease. EBA is characterized by the presence of circulating and
tissue-bound antibodies to type VII collagen (COL7), a major
component of anchoring ﬁbrils (Ludwig, 2013; Sakai et al.,
1986; Schmidt and Zillikens, 2013; Woodley et al., 1984;
Woodley et al., 1986). Pathogenicity of anti-COL7 autoanti-
bodies has been demonstrated in several experimental models
(Ludwig et al., 2013). Clinically, different EBA phenotypes are
described: (i) classical mechanobullous (Roenigk et al., 1971),
and (ii) inﬂammatory type, including bullous pemphigoid-
(Gammon et al., 1984), Brunsting-Perry pemphigoid- (Kurzhals
et al., 1991), linear IgA dermatosis- (Zambruno et al., 1994),
and mucous membrane pemphigoid-like variants (Dahl, 1979).
Whereas events leading to blister formation in the inﬂammatory
EBA variant are relatively well characterized, it remains unclear
which processes cause blistering in mechanobullous EBA––e.g.,
perturbation of interactions of COL7 and other components of
the dermal–epidermal junction (Gupta et al., 2012; Ishii et al.,
2010; Ludwig, 2012).
Detailed analysis of the autoantibody response in EBA
patients showed that, in the majority of cases, IgG anti-COL7
autoantibodies are detected. Characterization of IgG isotypes
demonstrated the prevalence of IgG1 and IgG4 subclasses
(Bernard et al., 1991; Oostingh et al., 2005). In addition, IgA
anti-COL7 reactivity, either exclusively or in combination
with IgG autoantibodies, is observed in 50–60% of patients
(Buijsrogge et al., 2011; Gandhi et al., 2000; Kim et al., 2011).
Yet, this understanding of the autoimmune response has not
been useful to differentiate among the mechanobullous and
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the inﬂammatory EBA variants (Gandhi et al., 2000). Epitope
mapping of the COL7-speciﬁc B-cell immune response in EBA
patients identiﬁed the NC1 domain of COL7 as the major
antigenic site (Gammon et al., 1993; Jones et al., 1995;
Tanaka et al., 1994). Binding of patient autoantibodies to the
collagenous or the NC2 domain is rarely observed (Ishii et al.,
2004; Saleh et al., 2011). Further epitope mapping of EBA
patients’ sera identiﬁed 4 major antigenic epitopes within the
NC1 domain (Chen et al., 2007; Gammon et al., 1993;
Gandhi et al., 2000; Ishii et al., 2004; Lapiere et al., 1993).
However, it remained unclear whether the speciﬁcities of the
anti-COL7 antibodies are associated with certain clinical EBA
phenotypes.
The pathogenic relevance of patient’s anti-COL7 IgG has
been demonstrated by its ability to induce dermal–epidermal
separation when incubated with cryosections of human skin in
the presence of neutrophils (Sitaru et al., 2002a) and by
induction of subepidermal blisters in mice, which were
injected with patient antibodies, afﬁnity-puriﬁed against the
NC1 domain (Woodley et al., 2006). Experimental EBA can
also be induced in mice by transfer of antibodies to epitopes
located within the murine sixth–ninth ﬁbronectin-3 (FNIII)-like
repeat or by immunization with the same antigen (Sitaru et al.,
2006; Sitaru et al., 2005). Furthermore, transfer of patient
autoantibodies, afﬁnity-puriﬁed against the cartilage matrix
protein (CMP) domain, also induced EBA after transfer into
mice (Chen et al., 2007). Recently, pathogenicity of anti-von
Willebrand factor 2 (anti-vWFA2) antibodies has been demon-
strated, both by transfer of autoantibodies and by immunization
of mice with vWFA2 (Iwata et al., 2013). Collectively, sera
from EBA patients bind to many epitopes located within the
NC1 domain, but pathogenicity has only been demonstrated for
few of these. It remains unclear whether the broad epitope
recognition observed in EBA patients is an epiphenomenon
resulting from intramolecular epitope spreading or whether this
broad recognition pattern is required for blister induction.
In a cohort of 69 EBA patients as well as in ex vivo and
in vivo models of EBA, we therefore here addressed whether
(i) the different clinical EBA phenotypes are associated with
certain autoantibody speciﬁcities, and (ii) whether autoanti-
bodies to certain domains of NC1 are capable to induce
subepidermal blisters.
RESULTS
Expression of recombinant subdomains of COL7 NC1
Recombinant overlapping proteins for NC1 subdomains and
NC2 domain were successfully produced in E. coli Rosetta
DE3 (Supplementary Figure S1). CMP-FNIII1 and FNIII9-
vWFA2 fragments were insoluble. After refolding, CMP-FNIII1
protein could be obtained in sufﬁcient amounts and purity for
rabbit immunization. FNIII9-vWFA2 protein purity did not
allow using this protein for raising rabbit antibodies. Correct
size of all proteins was conﬁrmed by SDS-PAGE gel analysis
(Supplementary Figure S1).
EBA patients’ sera recognize multiple epitopes within NC1
For determination of epitope recognition patterns of patient
autoantibodies, we analyzed IgG reactivity with recombinant
proteins of NC1 domain. In preliminary studies, IgG1, IgG2,
IgG3, and IgG4 secondary antibodies for detection of
reactivity to the recombinant fragments were evaluated for
speciﬁcity. Although the use of secondary antibodies speciﬁc
for IgG1, IgG2, and IgG3 showed high reactivity with normal
human sera, the use of IgG4 secondary antibodies did not or
only rarely show this unspeciﬁc binding (not shown). This is in
line with the routine diagnosis of EBA in our laboratory, where
an anti-IgG4 antibody is used for the same reason (Schmidt
and Zillikens, 2013). Furthermore, here (Supplementary Table
S1 online) and elsewhere (Komorowski et al., 2013) IgG4
reactivity correlated well with the COL7-speciﬁc binding of
other IgG to this protein. Therefore, subsequent epitope
mapping studies were carried out using anti-human IgG4 as a
secondary antibody. In most cases, the IgG4 reactivity pattern
in sera from EBA patients was not restricted to single epitopes,
but rather showed clusters of reactivity, recognizing multiple
subdomains of NC1 domain (Figure 1). Detailed analysis of
the number of epitopes recognized by EBA sera showed that
most sera (58%) had autoantibody reactivity to two stretches
(deﬁned as a continuous recognition of subsequent recombi-
nant proteins). The mean length of such stretches consisted on
an average of 3.5±2.7 recombinant proteins. Sera of 16
patients recognized a single stretch with a length of 7.2± 2.7
recombinant proteins; autoantibodies from 13 patients were
speciﬁc to three different stretches, mean length 2.0± 1.5. We
also generated recombinant NC2. In 41 tested sera from our
cohort of EBA patients, 9 reacted to this epitope.
Gender and age, but not the clinical EBA variant, correlate with
autoantibody speciﬁcity
To test whether certain epitope recognition patterns are
speciﬁc for the different clinical phenotypes of EBA, we
performed homogeneity distribution analysis and Pearson's
correlation coefﬁcient analysis. Interestingly, no statistically
signiﬁcant correlation was found between the recognized
epitopes within the NC1 domain and the clinical phenotype.
However, IgG4 binding pattern was dependent on age and
gender of the patients (Figure 2). Younger age was associated
with recognition of C-terminally located recombinant
proteins, as well as NC2. Male gender was associated with
recognition of FNIII2-FNIII3 and FNIII3-FNIII4 fragments.
Antibodies from female EBA patients bound more to FNIII8-
FNIII9 (Figure 2).
Autoantibodies against speciﬁc human NC1 subdomains show
intramolecular cross-reactivity and varying cross-reactivity
with murine skin
For functional studies, polyclonal rabbit anti-COL7 antibodies
were generated by immunizing rabbits with all recombinant
proteins spanning the human NC1 domain with the exception
of FNIII9-vWFA2. Subdomains of NC1 domain of COL7
consist of the ﬂanking CMP and vWFA2 domains and
9 FNIII-like repeats; these subdomains share some homology
(Parente et al., 1991). We ﬁrst evaluated the possibility of
intramolecular cross-reactivity of autoantibodies directed to
speciﬁc domains within NC1. For this, we performed western
blotting analysis using afﬁnity-puriﬁed anti-NC1 antibodies
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from rabbit sera and recombinant proteins. All antibodies
showed reactivity to the respective antigen. Interestingly, for
several antibodies, we observed binding to NC1 subdomains
outside of the used immunogen. For example, FNIII1-FNIII2
was recognized not only by the corresponding anti-CMP-
FNIII1, anti-FNIII1-FNIII2, and anti-FNIII2-FNIII3 antibodies
but also by anti-FNIII4-FNIII5, anti-FNIII5-FNIII6, and anti-
FNIII7-FNIII8 antibodies. (Figure 3a and b). Antibodies to NC2
were also generated. However, these did not bind to human
salt-split skin (not shown). The presence of intermolecular
cross-reactivity was also observed in the immunapheresis
material of an EBA patient (Supplementary Figure S2A and B
online).
Next, as NC1 portions of murine and human share some
homology, we evaluated whether antibodies to human COL7
can also recognize murine COL7. All our polyclonal anti-
COL7 antibodies bound to the dermal side of human salt-split
skin. Endpoint titers ranged from 1:1,600 (anti-FNIII2-FNIII3)
to 1:25,600 (anti-FNIII4-FNIII5 and anti-FNIII7-FNIII8) (Figure 3c).
Using murine skin as a substrate for indirect immunoﬂuo-
rescence microscopy, we observed binding of most anti-
bodies (Figure 3c). However, on murine skin, a similar endpoint
titer was only observed for anti-CMP-FNIII1, whereas no
binding to murine skin was observed for anti-FNIII3-FNIII4
and anti-FNIII7-FNIII8. All other antibodies showed a lower
endpoint titer on murine, compared with human, skin.
Antibodies to different epitopes of COL7 induce dermal–
epidermal separation ex vivo
We next determined the ability of anti-COL7 autoantibodies
to induce dermal–epidermal separation ex vivo by incubating
our anti-COL7 autoantibodies with cryosections of human
skin in the presence of leukocytes. Interestingly, all anti-COL7
autoantibodies recruited leukocytes to the dermal–epidermal
junction and caused dermal–epidermal separation, located in
lamina lucida (Figure 4,Supplementary Figure S3 online). This
is in line with previous observations of intra-lamina lucida
blister formation in EBA patients (Fine et al., 1989). For most
immune sera tested, the extent of dermal–epidermal separa-
tion correlated with antibody concentration (Figure 4). Preim-
mune sera neither recruited leukocytes to the dermal–epidermal
junction, nor induced dermal–epidermal separation.
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Figure 1. Epidermolysis bullosa acquisita (EBA) patients’ sera recognize
multiple epitopes within the non-collagenous 1 (NC1) domain. (a) Schematic
representation of the epitope-speciﬁc reactivity of 69 EBA patients’ sera tested
by western blotting. The y axis corresponds to the number of EBA patient sera
reacting with the epitopes speciﬁed on the x axis. (b) Representative images of
western blotting analysis of selected EBA patients’ sera. Bands show reactivity
of 18 EBA sera with different recombinant proteins of human type VII collagen
NC1. As negative controls, randomly selected normal human sera were used.
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To validate these ﬁndings using human sera, we afﬁnity-
puriﬁed IgG antibodies direct against the different epitopes
within the NC1 domain from immunoapheresis material from
one EBA patient. Here, we could isolate IgG antibodies
against all NC1 fragments used within the study. The obtained
material was not sufﬁcient to be tested in the above ex vivo
dermal–epidermal separation assay. To test for a possible
neutrophil activating capability of these autoantibodies, we
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Figure 3. The presence of intramolecular cross-reactivity of antibodies to type VII collagen (COL7) non-collagenous 1 (NC1) and cross-reactivity of antibodies
between human and murine skin. (a) Summary and (b) corresponding images of western blotting analyses, showing cross-reactivity of immune sera with
recombinant fragments of human COL7. Marked in red is reactivity outside the antigen used for immunization. (c) Summary and corresponding images of end
point titers of the generated rabbit immune sera, speciﬁc to different subdomains of COL7 NC1, on human 1 M salt-split skin (marked with h) and murine skin
(marked with m) by indirect immunoﬂuorescence microscopy. Bar= 100 μm. Serum dilutions used for the shown images were adjusted to a 100-fold lower
dilution compared with the end point titer of each epitope-speciﬁc serum determined on human skin as substrate. For immunoﬂuorescence images on human and
murine skin, the same serum dilutions were used. The summary table on the left side of top panel shows end point titers of the subdomain-speciﬁc sera on human
salt-split skin and murine skin. Abbreviations: C-1, CMP-FNIII1, 1-2, FNIII1-FNIII2, all other abbreviations correspond to this format.
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generated immune complexes using the different afﬁnity
puriﬁed antibodies and recombinant NC1 protein. In parallel
to above ﬁndings using rabbit immune sera, immune com-
plexes of NC1 and either one of the afﬁnity-puriﬁed IgG were
able to activate neutrophils (Supplementary Figure S2C
online).
Antibodies to different epitopes of COL7 cause blister formation
when injected into COL7m− /− ,h mice
To validate ﬁndings from the ex vivo assay in vivo, afﬁnity-
puriﬁed antibodies against FNIII4-FNIII5 and FNIII7-FNIII8
subdomains were injected into COL7m− /− ,h+ (COL7-huma-
nized) mice. Injection of either one of these antibodies into
COL7-humanized mice induced clinical and histological
changes resembling human EBA (Figure 5). In detail, skin
lesions were apparent already on the fourth day after initial
injection of antibodies. To assess whether the effect of these
anti-COL7 antibodies was dose dependent, lower doses were
injected. In fact, these experiments showed a dose-dependent
effect of the antibodies in the skin of COL7-humanized mice.
To further characterize this EBA mouse model, F(ab)2
fragments of these anti-COL7 IgG were generated. When
injected at an equimolar concentration, mixture of anti-
FNIII4-FNIII5 and anti-FNIII7-FNIII8 induced subepidermal
blisters, the corresponding F(ab)2 fragments did not induce
any clinical or microscopic phenotype (Supplementary Figure
S4 online). Investigation of the inﬁltrating cells showed a
predominance of neutrophils in the skin lesions (Figure 5,
Supplementary Figure S4 online).
DISCUSSION
We here performed a detailed epitope mapping of reactivity
to COL7 using 69 sera from EBA patients. By immunoblotting,
we demonstrate a broad spectrum of epitopes located within
the NC1 domain that are targeted by the autoantibodies. We
next demonstrated that autoantibodies to different epitopes
induce blisters ex vivo. This ﬁnding was conﬁrmed by
injection of two different anti-COL7 antibodies into mice
carrying null mutations of mouse COL7 and the human COL7
transgene (COL7m− /− ,h+), which induced subepidermal
blisters resembling EBA. Although previous studies clearly
demonstrated in vivo pathogenicity of autoantibodies to
mouse COL7 (Chen et al., 2007; Sitaru et al., 2005;
Woodley et al., 2005; Woodley et al., 2006), we here pro-
vide in vivo evidence of the pathogenicity of autoantibodies
directed to human COL7.
According to clinical presentation, mechanobullous and
inﬂammatory EBA is distinguished. In addition, clinical
presentation of an individual EBA patient may change during
the course of the disease or may show two different pre-
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Figure 4. Anti-type VII collagen (anti-COL7) non-collagenous 1 (NC1) antibodies induces dermal–epidermal separation ex vivo independent of the targeted
epitope. Cryosections of human skin were incubated with epitope-speciﬁc rabbit anti-human COL7 NC1 antibodies for 1 hour and subsequently with leukocytes from
healthy volunteers for 3 hours. All sera were used as pure 1:2, 1:4, and 1:8 dilutions. On the y axis, the percentage of dermal–epidermal separation is shown. Each
experiment was performed ﬁve times with leukocytes from ﬁve volunteers. SEM is depicted. Representative results for each experiment are shown (bar=100 μm).
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sentations simultaneously. The clinical distinction between
mechanobullous and inﬂammatory EBA has so far, however,
not been reﬂected by laboratory ﬁndings––e.g., autoantibody
subclasses (Gupta et al., 2012). As binding of autoantibodies
to the vWFA2-domain of NC1 leads to disruption of COL7/
COL1 interactions, as shown by nuclear magnetic resonance
(Leineweber et al., 2011), and as interactions of COL7
with both COL4 and laminin-332 have been described
(Brittingham et al., 2006; Chen et al., 1997; Rousselle et al.,
1997), we hypothesized that autoantibody binding to certain
epitopes within the NC1 domain of COL7 is associated with a
distinct EBA phenotype. However, in our cohort of 69 EBA
patients, we found no correlation of clinical phenotype with
the ﬁne speciﬁcity of anti-COL7 IgG. We do not think that
reactivity to the collagenous domain of COL7 can explain
these ﬁndings, as only very few patients had been described
to have reactivity to epitopes located within the collagenous
domain and/or the hinge region of COL7 (Ishii et al., 2009).
Hence, other factors are likely to cause the different clinical
phenotypes. In an antibody-transfer model of the disease,
inbred mouse lines showed different susceptibilities to blister
induction; e.g., in C57BL6/J, the extent of clinical disease was
higher compared with BALB/C mice (Kasperkiewicz et al.,
2012). As the immune system differs among inbred mouse
lines, mechanobullous EBA may develop in patients who do
not mount a strong inﬂammatory reaction in response to
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binding of autoantibodies to COL7, if the autoantibody targets
a structurally relevant epitope. Careful clinical observations
together with stringent immunophenotyping––e.g., analyzing
the patients’ neutrophils for the ability to mount an oxidative
burst upon stimulation with autoimmune complexes––will
allow testing this assumption. In line with this assumption, a
major interindividual variation of immune complex-induced
neutrophil activation has been described (Recke et al., 2010).
After demonstrating a broad epitope recognition of EBA
patient IgG, we next evaluated the potential of antibodies
targeting different epitopes of NC1 to induce subepidermal
splits. When these antibodies were tested for reactivity with the
proteins used for immunization, binding to epitopes outside
these proteins was observed for anti-FNIII3-FNIII4, anti-FNIII5-
FNIII6, anti-FNIII6-FNIII7, anti-FNIII7-FNIII8, and anti-FNIII8-
FNIII9 antibodies. This phenomenon may be explained by the
high homology among the FNIII-like repeat domains. Hence, in
EBA patients, an autoantibody may cross-react with different
epitopes on COL7. In addition to inter- and intramolecular
epitope spreading (Di Zenzo et al., 2011), this binding of an
individual antibody to different epitopes underscores the
complexity of the autoimmune response in acquired bullous
dermatoses. Although the epitope mapping study used IgG4 as
a surrogate marker for the total IgG reactivity to COL7 for
sensitivity and speciﬁcity purposes, we here either used whole
patient IgG or used whole immune IgG from rabbits.
We further showed that all antibodies generated here,
which were directed to different epitopes of human COL7
NC1, led to dermal–epidermal separation ex vivo, as reported
previously using other fragments of COL7 (Csorba et al.,
2010). Split formation was dependent on the presence of
neutrophils, whereas incubation of human skin with anti-
bodies alone did not cause pathology. This is in line with
previous observations demonstrating that patients’ antibodies,
puriﬁed against the entire human NC1 domain, depend on
the presence of neutrophils (Sitaru et al., 2002a), more
speciﬁcally, on generation of reactive oxygen species (Chiriac
et al., 2007) and proteases (Shimanovich et al., 2004). To
validate the blister-inducing potential of the generated
antibodies in vivo, rabbit anti-FNIII4-FNIII5 or anti-FNIII7-
FNIII8 was injected into COL7-humanized mice. Both these
antibody preparations bound to the dermal–epidermal junc-
tion, led to complement deposition, and induced subepider-
mal blisters in a dose-dependent manner, resembling the
inﬂammatory variant of human EBA. This blistering pheno-
type underscores the pathogenic relevance of the used
antibodies, as mere binding of autoantibodies to the dermal–
epidermal junction, i.e. formation of immune complexes,
does not inevitably lead to blister formation. For example, this
is reﬂected by the lack of blister formation, despite of IgG
deposition at the dermal–epidermal junction in mouse models
of EBA (Ludwig et al., 2012; Sitaru et al., 2006) and bullous
pemphigoid (Liu et al., 1995). This EBA animal model also
provides direct evidence that binding of antibodies to human
COL7 induces blistering in vivo. Previous mouse models of
EBA demonstrated pathogenicity of antibodies, directed to
mouse or human COL7, that bound murine COL7 in vivo
(Chen et al., 2007; Sitaru et al., 2006; Sitaru et al., 2005;
Woodley et al., 2005). The pathogenicity of different IgG
subclasses, as well as IgA directed against COL7, still remains
a controversial issue: although some data suggest a potential
of IgG4 to induce subepidermal splits ex vivo (Mihai et al.,
2007), others have demonstrated opposite ﬁndings (Recke
et al., 2010). Furthermore, IgA has recently been demon-
strated to lead to subepidermal splits ex vivo (Recke et al.,
2014; van der Steen et al., 2012). On the basis of the
developed animal model here, these ﬁndings can now be
addressed in vivo to investigate the potential pathogenic
contribution of IgA, as well as IgG subclasses in EBA.
In summary, our mapping studies with NC1 and NC2
domains of COL7 show that autoantibodies in EBA patients
recognize a broad spectrum of epitopes within COL7 NC1.
No correlation was detected between antibody speciﬁcity and
clinical phenotype. Both ex vivo and using COL7 humanized
mouse in vivo, these autoantibodies induce subepidermal
blisters, independent of their speciﬁcity. Furthermore, we
demonstrate intramolecular cross-reactivity of autoantibodies
directed to a speciﬁc epitope within the NC1 domain.
MATERIALS AND METHODS
A more detailed description of the materials and methods used is
provided in the Supplementary Materials and Methods online.
Patient sera and human skin
Serum samples from 69 EBA patients for detection of circulating anti-
COL7 antibodies were used in this study. As the presence of
circulating anti-COL7 antibodies was required for epitope mapping
studies, EBA patients diagnosed by detection of an u-serrated pattern
in the absence of circulating autoantibodies (Buijsrogge et al., 2011)
were not included. Sera from healthy volunteers served as controls.
Neonatal human foreskin, obtained from routine circumcision, was
snap, cut in 6 μm sections, and mounted on SuperFrost slides
(Thermo Scientiﬁc, Braunschweig, Germany). Prior to all procedures,
written informed consent was obtained from all patients. The study
was approved by the ethics committee of the University of Lübeck
and was performed according to the Declaration of Helsinki.
Mice
COL7m− /− ,h+ (COL7-humanized) mice that carry the homozygous
null mutations of mouse Col7a1 genes and the transgene of human
COL7A1 were generated as described previously (Ito et al., 2009).
COL7-humanized mice aged 6–8 weeks were intraperitoneally
injected with 100–500 μg in a total of rabbit antibody speciﬁc to
NC1 domain of human COL7 or phosphate-buffered saline (PBS) at
days 0, 2, and 4. The extent of blistering was evaluated at days 4, 8,
and 12 after the initial IgG injection. Skin samples for hematoxylin
and eosin staining and direct immunoﬂuorescence microscopy and
serum samples were obtained at day 12. All animal procedures were
conducted according to guidelines of the Hokkaido University
Institutional Animal Care and Use Committee under an approved
protocol.
Cloning of cDNA clones for human NC1 and NC2 domains of
COL7 recombinant proteins
DNA sequence of the NC1 and NC2 domains was obtained from
Uniprot database (www.uniprot.org).
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Expression and puriﬁcation of recombinant proteins
E. coli Rosetta DE3 cells were transfected with plasmids. Recombi-
nant proteins were puriﬁed by afﬁnity chromatography using chitin
beads (New England Biolabs, Ipswich, MA). As proteins CMP-FNIII1
and FNIII9-vWFA2 were puriﬁed from inclusion bodies as described
(Hirose et al., 2011), they were refolded using oxidized-reduced
glutathione buffer, dialyzed against protein elution buffer, and
puriﬁed by afﬁnity chromatography over chitin beads.
Western blotting with patient sera
Please see Supplementary Materials and Methods online.
Rabbit polyclonal antibody production
Rabbit polyclonal antibodies against different fragments of COL7
were produced as previously described (Sitaru et al., 2005).
IgG was puriﬁed from preimmune and postimmune serum using
protein G-agarose as described (Sitaru et al., 2005). Corresponding F
(ab)2 fragments were generated using the F(ab)2 preparation kit
(Thermo Scientiﬁc, Rockford, IL) according to the manufacturer’s
protocol.
Indirect immunoﬂuorescence microscopy
Indirect immunoﬂuorescence studies were performed on murine and
1 M NaCl-split human skin. Cryosections of mouse skin and human
salt-split skin of 6-μm thickness were incubated with serial dilutions
of immune rabbit serum for 1 hour at room temperature, washed with
PBS, and then treated with 1:100 diluted FITC-conjugated polyclonal
swine-anti rabbit Ig (Dako, Hamburg, Germany).
Afﬁnity puriﬁcation of antibodies from rabbit serum
Recombinant proteins were dialyzed in 0.1 M MOPS, pH 7.5, and
coupled to Afﬁ-Gel 10 or 15 (according to isoelectric point of
proteins) following the manufacturer’s protocol (Bio-Rad, Munich,
Germany). IgG previously puriﬁed from postimmune serum was
afﬁnity-puriﬁed using corresponding Afﬁ-Gel coupled recombinant
proteins, then dialyzed against PBS, and concentrated by Amicon
Ultra (30 KDa, Millipore, Billerica, MA).
Afﬁnity puriﬁcation of antibodies from EBA patient serum
Plasmapheresis material from EBA patient was afﬁnity-puriﬁed using
corresponding Afﬁ-Gel coupled recombinant proteins, then dialyzed
against PBS, and concentrated by Amicon Ultra (30 KDa, Millipore,
Billerica, MA).
Puriﬁcation of normal human leukocytes
Leukocytes were isolated from heparin-anticoagulated blood of ﬁve
different healthy volunteers following a published protocol (Sitaru
et al., 2002b). Leukocytes used in this study (determined by trypan
blue) had a viability of ⩾ 90%.
Immune-complex activation of human leukocytes in vitro
Please see Supplementary Materials and Methods online.
Determination of dermal–epidermal separation ex vivo
Cryosections of 6-μm thickness human foreskin were incubated with
different dilutions of rabbit serum (pure, 1:2, 1:4, 1:8, 1:16) for 1 hour
at 37 °C, washed with PBS, and subsequently incubated with normal
human leukocytes from ﬁve different healthy donors at 37 °C for
3 hours. As a negative control, preimmune rabbit serum was used.
Subsequently, sections were washed and stained with hematoxylin
and eosin. Percentage of dermal–epidermal separation was evaluated
by two investigators unaware of the section treatment.
Statistical analysis
R was used for statistical analyses (R Foundation for Statistical
Computing, Vienna, Austria). A P-valueo0.05 was considered signiﬁcant.
Correlation of epitopes with gender, age, and clinical phenotype was
assessed by homogeneity distribution analysis and Pearson’s corre-
lation. For Pearson’s correlation, the coefﬁcient analysis WGCNA
package was used. Homogeneity distribution analysis was performed
using homals package.
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